These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 11839652

  • 21. A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993).
    Coleman RE, Biganzoli L, Canney P, Dirix L, Mauriac L, Chollet P, Batter V, Ngalula-Kabanga E, Dittrich C, Piccart M.
    Eur J Cancer; 2006 May; 42(7):882-7. PubMed ID: 16520033
    [Abstract] [Full Text] [Related]

  • 22. Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma.
    Hau P, Fabel K, Baumgart U, Rümmele P, Grauer O, Bock A, Dietmaier C, Dietmaier W, Dietrich J, Dudel C, Hübner F, Jauch T, Drechsel E, Kleiter I, Wismeth C, Zellner A, Brawanski A, Steinbrecher A, Marienhagen J, Bogdahn U.
    Cancer; 2004 Mar 15; 100(6):1199-207. PubMed ID: 15022287
    [Abstract] [Full Text] [Related]

  • 23. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients.
    Hussein MA, Wood L, Hsi E, Srkalovic G, Karam M, Elson P, Bukowski RM.
    Cancer; 2002 Nov 15; 95(10):2160-8. PubMed ID: 12412170
    [Abstract] [Full Text] [Related]

  • 24. Prediction of response to repeat utilization of anthracycline in recurrent breast cancer patients previously administered anthracycline-containing chemotherapeutic regimens as neoadjuvant or adjuvant chemotherapy.
    Yonemori K, Katsumata N, Kaneko M, Uno H, Matsumoto K, Kouno T, Shimizu C, Ando M, Takeuchi M, Fujiwara Y.
    Breast Cancer Res Treat; 2007 Jul 15; 103(3):313-8. PubMed ID: 17063267
    [Abstract] [Full Text] [Related]

  • 25. A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors.
    Seiden MV, Ng SW, Supko JG, Ryan DP, Clark JW, Lynch T, Huang KC, Kwiatkowski D, Skarin A, Eder JP.
    Clin Cancer Res; 2002 Mar 15; 8(3):691-7. PubMed ID: 11895897
    [Abstract] [Full Text] [Related]

  • 26. Phase I-II study of pegylated liposomal doxorubicin combined with weekly paclitaxel as first-line treatment in patients with metastatic breast cancer.
    Bourgeois H, Ferru A, Lortholary A, Delozier T, Boisdron-Celle M, Abadie-Lacourtoisie S, Joly F, Chieze S, Chabrun V, Gamelin E, Tourani JM.
    Am J Clin Oncol; 2006 Jun 15; 29(3):267-75. PubMed ID: 16755180
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer.
    Gordon AN, Tonda M, Sun S, Rackoff W, Doxil Study 30-49 Investigators.
    Gynecol Oncol; 2004 Oct 15; 95(1):1-8. PubMed ID: 15385103
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
    Kuhnt T, Becker A, Pigorsch S, Pelz T, Bloching M, Passmann M, Lotterer E, Hänsgen G, Dunst J.
    Strahlenther Onkol; 2003 Oct 15; 179(10):673-81. PubMed ID: 14566475
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.